Compare Ambarella Inc (AMBA) vs Summit Therapeutics Inc (SMMT) Price & Performance

Ambarella (AMBA) trades at $83.53, up 1.82% with bullish technical signals and strong analyst support. The company shows improving revenue trends ($405M projected for 2026) and consistent earnings beats, though profitability remains negative. Recent news highlights potential acquisition interest from NXP Semiconductors and strong positioning in edge AI markets.

Outlook remains positive with 58% analyst buy ratings and $108.67 price target, representing 30% upside. Key risks include ongoing net losses, competitive pressures in semiconductor space, and execution challenges in AI chip adoption. The stock offers growth exposure to physical AI trend but requires patience for profitability turnaround.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.